ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Phosphatidylserine-Targeting Nanobody Chimeras
Nanobodies engineered with phosphatidylserine-binding domains could selectively penetrate vesicles containing aggregated tau, as pathological tau aggregation disrupts membrane asymmetry and exposes PS on the inner leaflet.
molecular biology
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Nanobodies engineered with phosphatidylserine-binding domains could selectively penetrate vesicles containing aggregated tau, as pathological tau aggregation disrupts membrane asymmetry and exposes PS on the inner leaflet.
🧬 Mechanism
🔗 Mechanism from KG for MAPT
Auto-built from this analysis's top knowledge-graph edges.
graph TD
phosphatidylserine_exposu["phosphatidylserine exposure"] -->|associated with| APOPTOSIS["APOPTOSIS"]
pH_sensitive_membrane_fus["pH-sensitive_membrane_fusion_domain"] -->|activates| acidic_microenvironment["acidic_microenvironment"]
phosphatidylserine_bindin["phosphatidylserine-binding_domain"] -->|binds| phosphatidylserine["phosphatidylserine"]
curvature_sensitive_cell_["curvature-sensitive_cell_penetrating_peptide"] -->|penetrates| curved_membranes["curved_membranes"]
ATP_depleted_environment["ATP-depleted_environment"] -->|enables| membrane_penetration["membrane_penetration"]
tau_protein["tau_protein"] -->|interacts with| phosphatidylserine_1["phosphatidylserine"]
tau_protein_2["tau_protein"] -->|induces| membrane_curvature["membrane_curvature"]
tau_aggregation["tau_aggregation"] -->|causes| pH_acidification["pH_acidification"]
tau_aggregation_3["tau_aggregation"] -->|disrupts| cholesterol_depletion["cholesterol_depletion"]
tau_conformational_change["tau_conformational_change"] -->|triggers| membrane_disruption["membrane_disruption"]
tau_aggregation_4["tau_aggregation"] -->|causes| ATP_depletion["ATP_depletion"]
tau_aggregation_5["tau_aggregation"] -->|disrupts| membrane_asymmetry["membrane_asymmetry"]
style phosphatidylserine_exposu fill:#4fc3f7,stroke:#333,color:#000
style APOPTOSIS fill:#ce93d8,stroke:#333,color:#000
style pH_sensitive_membrane_fus fill:#4fc3f7,stroke:#333,color:#000
style acidic_microenvironment fill:#4fc3f7,stroke:#333,color:#000
style phosphatidylserine_bindin fill:#4fc3f7,stroke:#333,color:#000
style phosphatidylserine fill:#4fc3f7,stroke:#333,color:#000
style curvature_sensitive_cell_ fill:#4fc3f7,stroke:#333,color:#000
style curved_membranes fill:#4fc3f7,stroke:#333,color:#000
style ATP_depleted_environment fill:#4fc3f7,stroke:#333,color:#000
style membrane_penetration fill:#4fc3f7,stroke:#333,color:#000
style tau_protein fill:#4fc3f7,stroke:#333,color:#000
style phosphatidylserine_1 fill:#4fc3f7,stroke:#333,color:#000
style tau_protein_2 fill:#4fc3f7,stroke:#333,color:#000
style membrane_curvature fill:#4fc3f7,stroke:#333,color:#000
style tau_aggregation fill:#4fc3f7,stroke:#333,color:#000
style pH_acidification fill:#4fc3f7,stroke:#333,color:#000
style tau_aggregation_3 fill:#4fc3f7,stroke:#333,color:#000
style cholesterol_depletion fill:#4fc3f7,stroke:#333,color:#000
style tau_conformational_change fill:#4fc3f7,stroke:#333,color:#000
style membrane_disruption fill:#4fc3f7,stroke:#333,color:#000
style tau_aggregation_4 fill:#4fc3f7,stroke:#333,color:#000
style ATP_depletion fill:#4fc3f7,stroke:#333,color:#000
style tau_aggregation_5 fill:#4fc3f7,stroke:#333,color:#000
style membrane_asymmetry fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Supports
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Supports
Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration.
Contradicts
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Contradicts
Synergy between amyloid-β and tau in Alzheimer's disease.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MAPT
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAPT.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
12,936
$0.0776
Total Cost
$0.0776
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF PS-targeting nanobody chimeras selectively penetrate tau aggregates, THEN weekly intravenous administration for 8 weeks will reduce Sarkosyl-insoluble tau by ≥40% in the hippocampus of P301S transg | Quantifiable reduction in S396/S404 phosphorylated tau (PHF1 epitope) in the Sarkosyl-insoluble fraction from hippocampus, measured by ELISA or Western blot, wi | — no observation — | pending | 0.25 |
| IF we engineer nanobody chimeras containing phosphatidylserine-binding domains (Annexin V-derived) fused to anti-MAPT binding sequences (HJ9.3 or E3), THEN these chimeras will accumulate at ≥2-fold hi | Fluorescently labeled PS-targeting nanobody chimeras will show preferential accumulation in AT8-immunoreactive neurons, with mean fluorescence intensity ratio ( | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF we engineer nanobody chimeras containing phosphatidylserine-binding domains (Annexin V-derived) fused to anti-MAPT binding sequences (HJ9.3 or E3), THEN these chimeras will accumulate at ≥2-fold higher levels in tau-aggregation-positive neurons compared to tau-negative neurons within 2 hours of e
Predicted outcome: Fluorescently labeled PS-targeting nanobody chimeras will show preferential accumulation in AT8-immunoreactive neurons, with mean fluorescence intensi
Falsification: No significant difference in accumulation (ratio <1.5 with p>0.05) between tau-aggregate-positive and tau-aggregate-negative neurons, or accumulation equivalent to non-PS-targeting nanobody controls.
pendingconf 25%
IF PS-targeting nanobody chimeras selectively penetrate tau aggregates, THEN weekly intravenous administration for 8 weeks will reduce Sarkosyl-insoluble tau by ≥40% in the hippocampus of P301S transgenic mice compared to vehicle-treated controls.
Predicted outcome: Quantifiable reduction in S396/S404 phosphorylated tau (PHF1 epitope) in the Sarkosyl-insoluble fraction from hippocampus, measured by ELISA or Wester
Falsification: No statistically significant reduction in Sarkosyl-insoluble tau levels (p>0.05 by t-test) or equivalent outcome in vehicle vs. treatment groups; histological NFT burden unchanged.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.